Clinical significance of p53 alterations in surgically treated prostate cancers

摘要: Despite the high number of previous studies, role p53 alterations in prostate cancer is not clearly defined. To address biology, a total 2514 cancers treated by radical prostatectomy were successfully analyzed immunohistochemistry tissue microarray format. Overall low rate p53-positive tumors was found (2.5%). A significant underestimation cases excluded subsequent large section analyses and direct sequencing gene subsets our patients. Large analysis 23 considered negative on yielded only one weakly tumor. Only 4 out 64 (6.4%) high-grade tumors, that for immunohistochemistry, presented exon 5–8 mutations. These data suggest sensitivity approach confirm overall frequency clinically localized cancer. positive immunostaining strongly associated with presence mutations (P<0.0001), advanced pT-stage Gleason grade surgical margins (P=0.03) early biochemical tumor recurrence (P<0.0001). higher detected late-stage diseases including metastatic (P=0.0152) hormone-refractory (P=0.0003). Moreover, expression identified as an independent predictor subgroup low- intermediate-grade cancers. In summary, results this study show characterize small biologically aggressive risk progression after prostatectomy. The increases progression.